Drug Approval | August 12, 2021
Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness
A treatment to prevent extreme symptoms and cut hospitalisation
A treatment to prevent extreme symptoms and cut hospitalisation
The drug is indicated for mild and transient episodes of heart block
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The facility is expected to be completed in 2024
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
Subscribe To Our Newsletter & Stay Updated
